Explore the literature behind our science


Featured on Covers


Liu, X., et al, 2023

Cancer Cell

Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity

Villanueva, V., et al, 2022

Translational Research

CD11b agonists offer a novel approach for treating lupus nephritis

Martinez, L., et al, 2020

Journal of Immunology

Cover Feature: A Genetic Model of Constitutively Active Integrin CD11b/CD18 

Geraghty T., et al, 2020

Frontiers in Oncology

Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer

Panni, R., et al, 2019

Science Translational Medicine

Cover Feature: Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies

Schmid, MC., et al, 2018

Nature Communications

Integrin CD11b activation drives anti-tumor innate immunity

Dickinson, C., et al, 2018

Journal of intensive care

Leukadherin-1 ameliorates endothelial barrier damage mediated by neutrophils from critically ill patients

Khan, S., et al, 2018

Frontiers of medicine

CD11b Activity Modulates Pathogenesis of Lupus Nephritis

Faridi, MH., et al, 2017

Journal of clinical investigation

CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus

Johnson, CM., et al, 2016

Journal of Immunology

Integrin Cross-Talk Regulates the Human Neutrophil Response to Fungal β-Glucan in the Context of the Extracellular Matrix: A Prominent Role for VLA3 in the Antifungal Response

Jagarapu, J., et al, 2015

American Journal of Respiratory Cell and Molecular Biology

Leukadherin-1 Attenuates Hyperoxia-induced Lung Injury in Neonatal Rats

Khan, SQ., et al, 2014

Frontiers of medicine

A Small Molecule β2 Integrin Agonist Improves Chronic Kidney Allograft Survival by Reducing Leukocyte Recruitment and Accompanying Vasculopathy

Celik E., et al, 2013

Biophysical Journal

Agonist leukadherin-1 increases CD11b/CD18 dependent adhesion via membrane tethers

Faridi MH., et al, 2013

Biochimica et Biophysica Acta

Small molecule agonists of integrin CD11b/CD18 do not induce global conformational changes and are significantly better than activating antibodies in reducing vascular injury

Reed, RH., et al, 2013

Journal of Biological Chemistry

Complement receptor 3 influences Toll-like receptor 7/8 dependent inflammation: implications for autoimmune diseases characterized by antibody reactivity to ribonucleoproteins

Maiguel D., et al, 2011

Science Signaling

Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease

Faridi MH., et al, 2010

Biochemical and Biophysical Research Communications

High-throughput screening based identification of small molecule antagonists of integrin CD11b/CD18 ligand binding

Faridi MH., et al, 2009

Bioorganic & Medicinal Chemistry Letters

Identification of novel agonists of the integrin CD11b/CD18

Park, JY., et al, 2007

Journal of Biomolecular Screening

A simple, no-wash cell-adhesion based high throughput assay for the discovery of small molecule regulators of the integrin CD11b/CD18


Reiser J., et al, 2010

Kidney International

Toward the development of podocyte-specific drugs

Lee, HW., et al, 2017

American Journal of Physiology-Renal Physiology

High-content screening assay-based discovery of paullones as novel podocyte-protective agents

Gupta V., Reiser J., 2016

American Journal of Physiology-Renal Physiology

Stop that podocyte!

Lee HW., et al, 2015

Journal of the American Society of Nephrology

Cover Feature: A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules

© 2023 AlloSite Therapeutics.       All rights reserved.